5 research outputs found
Immunohistological score of transcription factor 21 had a positive correlation with its urinary excretion and proteinuria in immunoglobulin a nephropathy
Transcription factor 21 (TCF21) contributes
to mammalian nephrogenesis, and especially to
glomerular maturation. Our previous study suggested its
influence on glomerular injury, showing that TCF21
expression in podocytes had a positive correlation with
the urinary protein value and also with the urinary
TCF21 concentration. We now focus on its influence on
the clinical course of immunoglobulin A nephropathy
(IgAN), as patients with IgAN constitute the largest
population of individuals with primary chronic
glomerulonephritis in the world. Twenty cases of IgAN
were divided into two groups according to the
immunohistological score (IHS) of glomerular TCF21
expression: group IHS1 (n=7) and group IHS2+3
(n=13). Sixteen of the 20 cases were followed up for 2
years. Group IHS2+3 had heavier urinary protein
(p=0.03) and a greater urinary TCF21 level (p<0.001)
compared to group IHS1 at baseline. None of the other
factors including hematuria, estimated glomerular
filtration rate (eGFR), or the Oxford classification
showed a statistically significant difference between
these two groups. At the 2-year follow-up, even though
the rate of remission in urinary protein, hematuria and
the eGFR decline were not statistically correlated to
IHS, the IHS2+3 group had a slight tendency toward a
steeper eGFR decline compared to IHS1 (p=0.31). The
present study suggested that the higher IHS of TCF21
corresponded to heavier proteinuria and a higher urinary
TCF21 level in IgAN. This could be the first step in
determining the TCF21 value for predicting the
prognosis for IgAN
Transcription factor 21 expression in injured podocytes of glomerular diseases
International audienceTranscription factor 21 (TCF21) is one of the essential transcription factors in kidney development. To elucidate its influence on glomerular disease, we have investigated TCF21 expression in human and rat kidney tissue, and its urinary concentration. Immunohistological analysis suggested the highest TCF21 expression in nephrotic syndrome along with the urinary protein level. Urinary TCF21 concentration in human showed a positive correlation with its podocyte expression level. In nephrotic rat models, TCF21 expression in podocytes increased along with the severity of nephrotic syndrome. Next, in vitro experiments using Tcf21-expressing murine podocyte cell line, we could observe some Tcf21-dependent effects, related with actin cytoskeleton dysregulation and apoptosis. Our study illustrated TCF21 expression changes in vivo and its in vitro-functional significance injured podocytes
Nano-dot markers for electron tomography formed by electron beam-induced deposition: Nanoparticle agglomerates application
Anti‐tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC‐dependent vulnerability
Abstract The modulation of pre‐mRNA splicing is proposed as an attractive anti‐neoplastic strategy, especially for the cancers that exhibit aberrant pre‐mRNA splicing. Here, we discovered that T‐025 functions as an orally available and potent inhibitor of Cdc2‐like kinases (CLKs), evolutionally conserved kinases that facilitate exon recognition in the splicing machinery. Treatment with T‐025 reduced CLK‐dependent phosphorylation, resulting in the induction of skipped exons, cell death, and growth suppression in vitro and in vivo. Further, through growth inhibitory characterization, we identified high CLK2 expression or MYC amplification as a sensitive‐associated biomarker of T‐025. Mechanistically, the level of CLK2 expression correlated with the magnitude of global skipped exons in response to T‐025 treatment. MYC activation, which altered pre‐mRNA splicing without the transcriptional regulation of CLKs, rendered cancer cells vulnerable to CLK inhibitors with synergistic cell death. Finally, we demonstrated in vivo anti‐tumor efficacy of T‐025 in an allograft model of spontaneous, MYC‐driven breast cancer, at well‐tolerated dosage. Collectively, our results suggest that the novel CLK inhibitor could have therapeutic benefits, especially for MYC‐driven cancer patients